Website intended for a NZ health professional readership
The window for active treatment of SSNHL is three weeks from initial symptoms, so it is important to make the consultation at first presentation a thorough one
1. Rauch SD. Idiopathic sudden sensorineural hearing loss. N Engl J Med 2008;359:833–40.
2. Wei BPC, Stathopoulos D, O'Leary S. Steroids for the treatment of sudden hearing loss with unknown cause. Cochrane, 2013.
3. Stachler RJ, Chandrasekhar SS, Archer SM et al. for the American Academy of Otolaryngology-Head and Neck Surgery. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg 2012 Mar;146(3 Suppl):S1–35.
4. Passamonti SM, Di Berardino F, Bucciarelli P et al. Risk factors for idiopathic sudden sensorineural hearing loss and their association with clinical outcome. Thromb Res 2015 Mar;135(3):508–12.
5. Battaglia A, Lualhati A, Lin H et al. A prospective, multi-centered study of the treatment of idiopathic sudden sensorineural hearing loss with combination therapy versus high-dose prednisone alone: a 139 patient follow-up. Otol Neurotol 2014 Jul. 35(6):1091–98.
6. Rauch SD, Halpin CF, Antonelli PJ et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA 2011;305(20):2071–79.
7. Kang WS, Yang CJ, Shim M et al. Prognostic factors for recovery from sudden sensorineural hearing loss: a retrospective study. J Audiol Otol 2017;21(1):9–15.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
